Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/BioNTech’s COVID-19 Vaccine Moves Into Adolescents; Adcomm To Weigh Broader Pediatric Issues

Executive Summary

Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.

You may also be interested in...



Will COVID-19 Vaccine Booster Shot Restore Full Immunity? Wait For Answer Almost Over

ACIP will discuss possible boosters for immunocompromised people next week. Pfizer’s head of vaccine R&D and BioNTech co-founder and CEO discuss whether neutralizing antibodies are necessary for protection against SARS-CoV-2, indication in children, and the low and high points of their collaboration at Stat summit.

COVID-19 Vaccines: Myocarditis Reports Could Slow Expansion Into Pediatric Age Groups

Concerns about cases of heart muscle inflammation occurring in older male adolescents and young men shortly after the second dose of Pfizer and Moderna mRNA vaccines hung over FDA advisory committee discussions on pediatric safety data requirements for COVID-19 vaccines; CDC’s ACIP will take up the myocarditis issue at an 18 June meeting.

Coronavirus Notebook: EMA To Decide On Comirnaty In 12-15-Year-Olds, Cuba Presses On With Homegrown Vaccine Rollout

At global level, Médecins Sans Frontières has called for all countries to support a revised version of the IP waiver for COVID-19 vaccines, singling out the recalcitrant European Commission for special attention.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel